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ABSTRACT The potential benefit of fish oil (omega-3 fatty
acids) consumption to reduce cardiovascular disease (CVD)
risk remains controversial. Some investigations report reduced
CVD risk associated with fish or fish oil consumption while
others report no benefit. This controversy is in part resolved
when consideration is given to omega-3 blood levels in rela-
tion to CVD risk as well as blood levels achieved in clinical
trials of omega-3 supplementation and CVD benefit. There is
a wide variation in omega-3 blood levels achieved between
individuals in response to a given dose of an omega-3 supple-
ment. Many studies tested a daily dose of 1 gram omega-3
supplementation. The individual variation in blood omega-3
levels achieved in response to a fixed daily dose helps to
explain why some individuals may obtain CVD protection
benefit while others do not due to failure to achieve a thera-
peutic threshold. Recent development of a population range in
a United States population helps to provide clinical guidance
since population omega-3 blood level ranges may vary due to
environmental and genetic reasons. Omega-3 supplementa-
tion may also be of benefit in reducing the adverse impact of
air pollution on CVD risk.
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Intoduction
The new AHA Cholesterol guidelines suggest determining
statin treatment strategy based on the risk classification of
the patient [1]. While this is a commendable approach, the
approximately 25 % relative coronary heart disease (CHD)
risk reduction attributed to statin treatment is actually only an
approximate 3.4 % absolute risk reduction. This approach
leaves many people still at elevated CHD risk despite statin
therapy [2]. Blood fish oil levels appears to reflect CHD risk
as well as clinical benefit following omega-3 treatment that
may be of clinical utility in the large group of patients that
remain at CHD risk despite statin treatment.
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Probably the first report of fish consumption as a medical
therapy is found in the Old Testament book of Tobias, “Then
the angel said to him: Take out the entrails of the fish, and lay
up his heart, and his gall, and his liver for thee; for these are
necessary for useful medicines.“ [3]. In relatively recent times
multiple studies have confirmed this observation. Large stud-
ies such as the Swedish Mammography cohort of 36,234
women followed for 8 years suggests moderate consumption
of fatty fish is associated with a lower risk for heart failure
hospitalization [4]. However, clinical trials of dietary modifi-
cation or fish oil consumption have not consistently reported
significant cardiovascular disease (CVD) event reduction
from fish oil intake. Part of the confusion surrounding the
different conclusions of these studies involves the assessment
of the effect of either a fixed daily dose of omega-3, or the
measurement of omega-3 blood levels achieved in each pa-
tient. The controversy regarding daily dose of fish oil versus
achieved blood level has recently been reviewed [5•]. This is
an important issue since wide variability in individual blood
level achieved, in response to a fixed dose of fish oil, has been
reported [5•]. In response to a fixed dose of fish oil, some
patients may achieve a therapeutic level while others may not.
In the past year new reports have contributed to the clarifica-
tion of this topic. The purpose of this article is to place recent
reports into clinical context regarding blood levels of omega-3
fatty acids and CVD risk or benefit.
Omega-3 fatty acid blood level measurement can be per-
formed in either plasma, serum, or red blood cell membranes.
Measurements with clinical utility include the “Omega-3
Index” which is the percent of fatty acids composed of
eicosapentaenoic acid (EPA)+docosahexaenoic acid (DHA),
the EPA/AA (arachadonic acid) ratio, EPA quantitation, and
DHA quantitation. Several laboratory methods are available
and include gas chromatography, red blood cell membrane
composition, and mass spectroscopy [6–8].
Controversey Remains
The controversy over potential CVD benefit of omega-3
fatty acids has not been resolved in the past two years.
A recent meta-analysis of 16,338 subjects treated with
omega-3 fatty acids and 16,318 control subjects did not
demonstrate satisfactory improvements in major cardio-
vascular events but omega-3 blood levels were not part
of the analysis [9]. However, in the same analyses,
significant reductions in risk of death from cardiac
causes was demonstrated reflecting a reduced CVD
mortality benefit from omega-3 supplementation. The
Singapore Chinese Health Study utilized a semi-
quantitative food-frequency questionnaire together with
mortality information in 63,257 Chinese adults with
890,473 person-years of follow up. Both EPA, DHA,
and ALA intake estimated from the food frequency
questionnaire were independently associated with re-
duced risk of CV mortality [10]. The Spanish EPIC
cohort study also estimated omega-3 fatty acid dietary
intake from a dietary questionnaire [11]. Contrary to the
Singapore study, the Spanish EPIC cohort did not reveal
any association of estimated EPA and DHA intake to
incident CHD in either men or women but neither study
assessed blood levels of omega-3 fatty acids achieved in
individual patients. Two recent 1 gram/day omega-3
supplement studies have reported no CV event benefit
after 1 year and 6.2 years of follow up [12, 13].
However similarly, neither of these studies investigated
the blood levels of omega-3 fatty acids achieved in
individual subjects. This is an important difference in
study design since an investigation such as the Multi-
Ethnic Study of Atherosclerosis (MESA), which did
measure blood levels of omega-3 fatty acids, has report-
ed that circulating EPA and DHA blood levels were
inversely and significantly associated with incident
CVD with a hazard ratio of 0.49 for the highest quartile
of blood EPA level and 0.39 for the highest quartile of
blood DHA, compared with the lowest quartile [14]. No
significant associations with CVD were observed for
alpha-linolenic acid or n-6 PUFA. This may be of
particular relevance due to the use of a 1 gram/day
omega-3 dose which may leave many patients below a
therapeutic threshold. Finally, part of the confusion may
involve the effect of omega-3 supplementation in pa-
tients based on the presence of other CHD risk factors.
The JELIS study reports that a 39 % (p=0.007) reduc-
tion in major coronary events was primarily seen in
patients who did not achieve LDL-C and non HDL-C
goals and concluded that EPA supplementation may be
most useful for those patients who cannot achieve blood
lipid goals [15].
The controversy regarding daily dose of omega-3 versus
individual blood levels achieved is further complicated by
including the concept of replacing dietary saturated fat with
omega-6 linoleic acid (LA). LA is found in high concentra-
tions in safflower oil, sunflower oil, cottonseed oil, corn oil,
and soybean oil. Initially recommended as replacements for
saturated fat in the diet, the findings of the Sydney Diet Heart
Study suggests this may be a mistake [16]. The Sydney Diet
Heart Study was a randomized controlled trial in 458 men
conducted between 1966 to 1973. The intervention group
received replacement of dietary fat with omega-6 linoleic acid
in the form of safflower oil and polyunsaturated margarine
and had higher rates of death than controls (17.6 % versus
11.8 %, hazard ratio 1.62) suggesting that substituting dietary
linoleic acid in place of saturated fats actually increased the
rates of death from all causes, CHD, and CVD. Thus, delete-
rious effects from LA included in omega-3 supplements may
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substant ia l ly a t tenuate a benef i t f rom omega-3
supplementation.
Variability in Individual Omega-3 Blood Level Response
to Treatment
Many fish oil clinical trials have used a dose of 1 g/d in all
treated subjects. The dose of 1 g/d of EPA, has been reported to
increase the total EPA+DHAblood levels from amean of 3.6%
to 5.4 % but approximately 16 % of the subjects achieved an
EPA+DHA blood level less than 4.8 % [17]. This is clinically
relevant since it has been noted that an EPA+DHA blood
level>5 % is the range in which dramatic reduction in sudden
coronary death reduction can be observed [17]. Individual var-
iability in blood level response to such a common dose could
leave a substantial number of patients at elevated CHD risk due
to failure to achieve a therapeutic EPA+DHA blood level. The
blood EPA/AA ratio is also a clinically relevant measurement
and has substantial individual variability in response to a fixed
dose. An EPA/AA ratio >0.75 has been associated with signif-
icantly lower major coronary events (MCE) in a Japanese
population [18•]. Laidlaw and colleagues have reported that
4 g/d of fish oil increased the mean EPA/AA ratio from approx-
imately 0.12 to 0.9 [19]. It is estimated that approximately 68%
of the subjects would have obtain an EPA/AA ratio of between
0.78 and 1.02 while 16 % would be less than 0.78. Thus, even
with 4 g/d omega-3 supplementation, approximately 16 % of
subjects would not have achieved the putative EPA/AA goal.
A portion of this variability is related to genetic differences
in fatty acid metabolism [20]. The ability to predict omega-3
index RBC response to therapy also depends on simple mea-
surements such as body weight. Flock and colleagues inves-
tigated the individual omega-3 index response to 0, 300, 600,
900, and 1800 mg/d of EPA+DHA supplementation and
reported that adding weight to the predictionmodel containing
EPA+DHA dosing changed predictive power of the response
variability from 68 % to 70 % (p<0.0001) and adding addi-
tional factors such as baseline omega-3 index, age, gender,
and physical activity further improved power of prediction of
treatment response to 78 % [21•].
Population Ranges
Blood omega-3 levels may vary for a variety of lifestyle (e.g.
fish consumption), geographic, and genetic reasons. In Japan
the mean EPA/AA ratio in patients requiring PCI was 0.40 and
in an asymptomatic population was 0.41 [22, 23•]. In these
two Japanese studies, both reported significant association
between EPA/AA ratio and coronary events despite the fact
that one enrolled patients with prior coronary event and the
other enrolled apparently health patients.
The difference is even more pronounced between different
ethnic groups. Mean and standard deviation values from
Caucasian individuals with sudden cardiac death compared to
a control group in the Physicians’ Health Study, revealed a
mean±SD (%) EPA of 1.72±0.59 and DHA 2.12±0.65 in the
sudden death group and EPA of 1.84±0.53 and DHA 2.38±
0.78 in the control group [24]. This reflects a mean omega-3
index of 3.84 % in the sudden death group compared to 4.22 %
in the control group. For the EPA/AA ratio, in a Japanese
population the mean±SD is reported to be 0.63±0.40 [25].
For individual patient values to be of clinical use it is often
useful to compare them to a reference range that is determined
from a population of the same nationality due to variability in
diet and environmental issues, and utilizing the same labora-
tory analysis method as the one utilized for patient manage-
ment. Many of the studies previously referred to were con-
ducted in Europe or Asia where variation in dietary and other
conditions may have resulted in omega-3 blood level ranges
different from those in the United States. For this reason a
reference range study was conducted in 1,101 healthy male
and female adults residing in the Los Angeles region to
determine laboratory reference ranges. Figure 1a represents
the omega-3 index reference range. For the omega-3 index,
the 25th percentile was 2.5 %, the 50th percentile was 3.7 %,
and the 75th percentile was 5.7 %. Figure 1b represents the
EPA/AA ratio in this healthy USA population and reveals a
25th percentile of 0.6, a 50th percentile of 1.0, and a 75th
percentile of 2.3. The mean and SD was 1.96±2.61.
EPA/AA Ratio as a Therapeutic Goal
The blood EPA/AA ratio is a clinically relevant measure-
ment. An EPA/AA ratio >0.75 has been associated with
significantly lower major coronary events (MCE) in a
Japanese population [26]. The EPA/AA ratio was also re-
ported to have a linear relationship with the ratio of prosta-
glandin (PG) I3 and PGI2 to thromboxane (TXA2) [27].
Most recently, the Hisayama Study evaluated the EPA/AA
ratio in 3,103 apparently healthy Japanese adults and report-
ed significantly increased incidence rates of CVD with lower
EPA/AA ratios [23•]. This was particularly evident in sub-
jects with hs-CRP≥1.0 mg/L but not in those with hs-CRP<
1.0 mg/L. In subjects with an EPA/AA ratio <0.29 but a hs-
CRP≥1.0 mg/L the age and sex adjusted incidence (per
thousand person years) was 23.3 compared to subjects with
the same EPA/AA ratio but hs-CRP<1.0 mg/L which was
8.2. The CVD risk increased 1.52 times per 0.20 decrement
in serum EPA/AA ratio in those with hs-CRP≥1.0 mg/L.
This association was not found for stroke in the Hisayama
study. In contrast, in Japanese patients with acute ischemic
stroke, early neurological deterioration (END) was reported
to be significantly associated with diabetes mellitus, hs-CRP,
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prior stroke, ischaemic heart disease, small vessel disease,
and the EPA/AA and DHA/AA ratios [28]. The investigators
concluded that a low serum n-3 PUFA/n-6 PUFA ratio on
admission may predict neurological deterioration with acute
ischemic stroke. The role of omega-3 fatty acids in patients
undergoing percutaneous coronary intervention (PCI) re-
mains a topic of interest but has a paucity of information.
Domei and colleagues recently reported on 284 PCI patients
with major adverse cardiac events (MACE) associated with
the PCI [22]. Analysis of serum omega-3 levels revealed
that only a high serum EPA/AA ratio was significantly
associated with a low incidence of MACE in multiple sta-
tistical models. A high level was defined as>0.404. This
remained significant after adjustment for age, diabetes, gen-
der, hypertension, LDL-C, and smoking.
Renal Disease
Maintenance hemodialysis therapy may impact omega-3
blood levels and CHD risk. In 517 patients, treated in
Japan, EPA/AA and DHA/AA ratios were significantly
reduced when compared to controls. Following adjust-
ment for age and other variables, the patients with the
lowest versus highest EPA+DHA/AA ratios exhibited
HRs in the range of 1.7 to 2.0 [29•]. Interestingly, the
absolute EPA, DHA, and AA concentrations were not
predictive of CVD. The authors concluded that in he-
modialysis patients, the serum PUFA profile is unfavor-
ably altered and that the low n-3 PUFA/AA ratios are
independently predictors of CVD.
In IgA Nephropathy patients, 2 years of treatment
with 3.35 g/d total omega-3 fatty acids EPA levels
increased from 0.8±0.5 to 3.1±1.3 % after treatment
and DHA from 3.7±1.6 to 6.5±1.3 %. Treatment with
6.70 g/d of omega-3 fatty acids increased blood EPA
levels from 0.9±0.6 to 5.2±1.8 % and blood DHA from
3.5±1.4 to 7.1±1.6 % [30]. In patients with IgA ne-
phropathy, treated with 4 gm/d fish oil, the mean EPA/
AA ratio increased from approximately 0.09±0.07 to
0.45±0.40 with a wide range of individual variability
[30–32].
Fig. 1 a Population distribution
EPA+DHA % in 1,101 subjects.
Mean=4.42 %, SD=2.59,
median=3.7 %. b Population
distribution EPA/AA ratio in
1,097 subjects. Mean=1.96,
SD=2.61, median=1.0
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Coronary Calcification
The Rotterdam Study reported that fish consumption was
correlated with coronary calcium scores [33]. In the
Honolulu Heart Study, Japanese living in Japan, had two-
fold higher blood levels of omega-3 fatty acids than both
Caucasian Americans living in Pennsylvania and Japanese
Americans living in Honolulu [34•]. The prevalence of CAC
in Japanese living in Japan was 9.3 %, in Caucasian
Americans, 26.1 %, and in Japanese Americans 31.4 %. The
highest median EPA+DHA% was associated with the lowest
CAC prevalence .While significant differences in CAC prev-
alence between Japanese living in Japan and Caucasians liv-
ing in America was present, these differences became non-
significant after adjusting for serum omega-3 fatty acid levels.
A recent investigation by Sekikawa and colleagues reported
on a follow-up study of 214 Japanese men and 152 Caucasian
men who initially had a calcium score of 0. After adjusting for
age, systolic blood pressure, LDL-C, diabetes the Japanese
men had a significantly lower incidence rate of CAC>10
compared to Caucasian men [34•]. After adjusting for
omega-3 fatty acids the ratio was attenuated and became
non-significant. The authors concluded that omega-3 fatty
acids significantly contribute to the difference in the incidence
of CAC between Japanese and Caucasian men.
Psychiatric and Depressive Disorders
Depression and psychiatric disorders have gained attention in
regard to CVD risk and outcomes. Depression following
myocardial infarction or cardiovascular procedures appears
to contribute to future cardiovascular events [35]. Fatty acids
are key components of normal brain function and omega-3
fatty acids may be important in this regard. A retrospective
study of Japanese patients with acute ischaemic stroke and
early neurological deterioration reported that blood levels of
EPA/AA and DHA/AAwere significantly and inversely asso-
ciated with early neurological deterioration [28].
Cancer Concern
The association of fish oil and prostate cancer dates back to at
least 1994 [36]. Environmental factors appear to play a role in
the development of hormone dependent cancers such as breast
and prostate. Dietary fat intake has been widely studied in
regard to risk for breast and prostate cancer but no definitive
conclusion has been developed. In-vitro and animal studies
indicate a protective effect of omega-3 fatty acids on the
progression of tumors [37]. Following an extensive review
of the epidemiologic data Terry and colleagues conclude that
given a general lack of studies that included important
measurements, such as type of fish consumed and tissue
concentrations of omega-3 fatty acids, there are too few stud-
ies to conclude that a relationship exists between marine fatty
acid intake and human cancer [38]. However, in 2011 Brasky
and colleagues reported, in 1,658 cases and 1,803 controls,
that serum levels of DHA (highest vs lowest quartile) were
associated with biopsy determined high-grade prostate cancer
but no fatty acids were associated with low-grade prostate
cancer [39].
In 2013 Chua and colleagues published a literature search
of 12 studies and concluded that high serum levels of DPA
were associated with reduced total prostate cancer risk and
that high levels of EPA and DHA could possibly be associated
with increased risk [40]. Like-wise, Sorongon-Legaspi and
colleagues published a meta-analysis of 6 case control and 6
nested case control studies also concluded that blood DPA had
an inverse relationship to prostate cancer risk and that EPA
and DHA had a positive association with high-grade prostate
cancer risk but only after adjustment of inter-study variability,
but advised caution in interpretation of the results [41]. Also in
2013 Torfadottir and colleagues published a report in 2,268
men using reported fish consumption but no blood measure-
ments [42]. They concluded that salted or smoked fish may
increase the risk of advanced prostate cancer whereas fish oil
consumption may be protective against progression of pros-
tate cancer in elderly men. In those with very high fish
consumption no association was found between fish con-
sumption, early or midlife, and prostate cancer risk.
Finally, Brasky and colleagues most recent report in 2013
generated considerable interest and is derived from the
Selenium and Vit E Cancer Prevention Trial. This study
reported an association of higher plasma linoleic acid with
reduced risk of low-grade and total prostate cancer and that
long chain fatty acids like EPA and DHAwere associated with
increased risk in this matched case control study [43].
Environmental Effects
Some adverse environmental effects may be impacted by fish
oils. Air pollution, and its adverse health consequences, is of
growing concern and studies have indicated that exposure to
ozone or air pollution particulate matter may increase angina
or CHD events [44, 45]. Low heart rate variability is an
independent predictor of sudden cardiac death, myocardial
infarction, heart failure and arrythmias in CHD patients [46].
An effect on heart rate variability (HRV) of 2 g/d fish oil
supplementation was reported in nursing home residents ex-
posed to ambient air pollution in Mexico City. Omega-3
supplementation reduced HRV lowering by air pollution from
−54 % pre-supplementation to −7 % post omega-3 supple-
mentation (p<0.01) [47]. This observation was tested in an
experimental chamber study. A randomized, double blind
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study of Tong and colleagues investigated the potential pro-
tective effects of 3 gm/day omega-3 fatty acids when healthy
middle aged adults were exposed to 2 hours of air pollution in
an experimental chamber [45]. This study revealed that expo-
sure to concentrated ambient fine and ultrafine particulate
matter (CAP) induced acute cardiac and lipid changes that
included significant elevations in triglycerides and VLDL-C
as well as lowering of heart rate variability and QT interval
changes. These parameters were not improved with olive oil
supplementation but were mitigated by 3 gm/d of marine
derived omega-3 fatty acids.
Conclusions
The controversy regarding the clinical role of enhanced fatty
fish consumption or omega-3 supplementation is gradually
becoming clear but some controversy remains. It is becoming
clear that blood levels of omega-3 fatty acids exhibit a rela-
tionship to CVD while fixed daily doses may not. First, as
reported in the JELIS investigation, the benefit of fish oil
consumption may be impacted by other risk factors such as
LDL-C and non-HDL-C levels. Second, recent reports such as
the MESA investigation confirm that reported circulating
blood levels of EPA and DHA are inversely and significantly
associated with reduced CHD event risk [14]. This supports
the interpretation that the blood levels of omega-3 fatty acids
achieved are more related to CVD benefit than the daily dose
of fish oil supplements [5•]. Third, in order to determine the
risk status of a patient, it is useful to have population ranges in
the country in which the patient resides, and many studies
have been conducted in either Japan or European countries. A
recent investigation of 1,102 healthy men and women living
in the Los Angeles region provides population ranges based
on a US population. Fourth, much like the TC/HDL-C ratio
provided a modestly improved CHD risk prediction ability,
the EPA/AA ratio also appears to provide clinical utility. This
appears to be of particular importance and the predictive
ability enhanced when other factors, such as elevated hs-
CRP, are present. Fifth, hemodialysis and nephropathy pa-
tients appear to be a group of patients that may benefit from
omega-3 blood level testing but have a wide range of individ-
ual variability in regard to blood level response to an omega-3
dose. Sixth, noninvasive CAC testing utilized for clinical
purposes of risk prediction and differences in CAC prevalence
between Japanese and United States individuals appears to be
linked to differences in omega-3 fatty acid blood levels.
Seventh, omega-3 blood levels may be associated with neu-
rological deterioration in ischemic stroke patients.
Research into the potential benefits of omega-3 fatty acids
will continue and should include fatty acid blood measure-
ments in individual patients. Currently clinical trial evidence
exists that provides physicians information on individual
patient risk classification and anticipated response to treatment
that may be of clinical value. Physician clinical judgment
remains an important element of excellent medical care and
the fish oil controversy is no exception to this rule.
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